Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 22:9:129.
doi: 10.3389/fnmol.2016.00129. eCollection 2016.

Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review

Ming Ming Wen  1
Affiliations
Review

Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review

Ming Ming Wen. Front Mol Neurosci. .

Abstract

miRNAs play important roles in modulating gene expression in varying cellular processes and disease pathogenesis, including neurodegenerative diseases. Several miRNAs are expressed in the brain, control brain development and are identified as important biomarkers in the pathogenesis of motor-and neuro-cognitive diseases such as Alzheimer's (AD), Huntington's and Parkinson's diseases (PD) and amyotrophic lateral sclerosis. These remarkable miRNAs could be used as diagnostic markers and therapeutic targeting potential for many stressful and untreatable progressive neurodegenerative diseases. To modulate these miRNA activities, there are currently two strategies involved; first one is to therapeutically restore the suppressed miRNA level by miRNA mimics (agonist), and the other one is to inhibit miRNA function by using anti-miR (antagonist) to repress overactive miRNA function. However, RNAi-based therapeutics often faces in vivo instability because naked nucleic acids are subject to enzyme degradation before reaching the target sites. Therefore, an effective, safe and stable bio-responsive delivery system is necessary to protect the nucleic acids from serum degradation and assist their entrance to the cells. Since neuronal cells are non-regenerating, to design engineered miRNAs to be delivered to the central nervous system (CNS) for long term gene expression and knockdown is representing an enormous challenge for scientists. This article provides an insight summary on some of the innovative strategies employed to deliver miRNA into target cells. These viral and non-viral carrier systems hold promise in RNA therapy delivery for neurodegenerative diseases.

Keywords: RNAi; anti-miR; gene; miRNA; molecular therapeutics; neurodegenerative disease.

PubMed Disclaimer

References

    1. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M. J. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345. 10.1038/nbt.1807 - DOI - PubMed
    1. Barzago C., Lum J., Cavalcante P., Srinivasan K. G., Faggiani E., Camera G., et al. . (2016). A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. Immunobiology 221, 1227–1236. 10.1016/j.imbio.2016.06.012 - DOI - PubMed
    1. Beutler A. S., Reinhardt M. (2009). AAV for pain: steps towards clinical translation. Gene Ther. 16, 461–469. 10.1038/gt.2009.23 - DOI - PubMed
    1. ClinicalTrials.gov (2012). MicroRNAs As Disease Markers for Central Nervous System Tumors in Patients with Neurofibromatosis Type 1. Available online at: https://www.clinicaltrials.gov/ct2/show/NCT01595139
    1. ClinicalTrials.gov (2013a). The Study of Microrna 107 (miRNA 107) and Beta-Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) Messenger Ribonucleic Acid (mRNA) Gene Expression in Cerebrospinal Fluid and Peripheral Blood of Alzheimer’s Disease. Available online at: https://www.clinicaltrials.gov/ct2/show/NCT01819545

LinkOut - more resources